Annovis Bio, Inc. (ANVS)
USD 4.71
(-7.83%)
USD 4.71
(-7.83%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -45.03 Million USD | -76.53% |
| 2022 | -25.51 Million USD | -75.49% |
| 2021 | -14.53 Million USD | -118.93% |
| 2020 | -6.64 Million USD | -313.56% |
| 2019 | -1.6 Million USD | -124.9% |
| 2018 | -713.93 Thousand USD | -4.62% |
| 2017 | -682.43 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -7.76 Million USD | 0.6% |
| 2024 Q1 | -7.8 Million USD | 25.21% |
| 2023 Q2 | -9.75 Million USD | -197.89% |
| 2023 Q3 | -14.71 Million USD | -50.79% |
| 2023 FY | -45.03 Million USD | -76.53% |
| 2023 Q1 | 9.96 Million USD | 414.61% |
| 2023 Q4 | -10.44 Million USD | 29.04% |
| 2022 Q3 | -7.67 Million USD | 12.33% |
| 2022 Q2 | -8.75 Million USD | -49.02% |
| 2022 Q1 | -5.87 Million USD | 0.77% |
| 2022 FY | -25.51 Million USD | -75.49% |
| 2022 Q4 | -3.16 Million USD | 58.71% |
| 2021 FY | -14.53 Million USD | -118.93% |
| 2021 Q4 | -5.92 Million USD | -107.45% |
| 2021 Q3 | -2.85 Million USD | -12.61% |
| 2021 Q2 | -2.53 Million USD | 21.52% |
| 2021 Q1 | -3.22 Million USD | -69.1% |
| 2020 Q4 | -1.9 Million USD | -19.07% |
| 2020 Q3 | -1.6 Million USD | 36.95% |
| 2020 Q2 | -2.54 Million USD | -336.18% |
| 2020 FY | -6.64 Million USD | -313.56% |
| 2020 Q1 | -583.16 Thousand USD | 33.04% |
| 2019 Q1 | -186.79 Thousand USD | -11.15% |
| 2019 Q4 | -870.96 Thousand USD | -260.21% |
| 2019 Q3 | -241.79 Thousand USD | 21.0% |
| 2019 FY | -1.6 Million USD | -124.9% |
| 2019 Q2 | -306.07 Thousand USD | -63.86% |
| 2018 Q4 | -168.05 Thousand USD | -22.0% |
| 2018 FY | -713.93 Thousand USD | -4.62% |
| 2018 Q3 | -137.74 Thousand USD | 36.86% |
| 2018 Q2 | -218.16 Thousand USD | -14.85% |
| 2018 Q1 | -189.96 Thousand USD | 0.0% |
| 2017 FY | -682.43 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ADC Therapeutics SA | -165.98 Million USD | 72.868% |
| Alto Neuroscience, Inc. | -37.8 Million USD | -19.112% |
| Biohaven Pharmaceutical Holding Company Ltd. | -436.05 Million USD | 89.672% |
| Ginkgo Bioworks Holdings, Inc. | -864.4 Million USD | 94.79% |
| Nuvation Bio Inc. | -99.82 Million USD | 54.885% |
| Nuvation Bio Inc. | -99.82 Million USD | 54.885% |
| Arcus Biosciences, Inc. | -340 Million USD | 86.754% |
| Theriva Biologics, Inc. | -21.43 Million USD | -110.14% |
| Zymeworks Inc. | -138.05 Million USD | 67.378% |